Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.

Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...

Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

If a current atopic dermatitis treatment isn’t working, it may be time for a change. Here’s how to confidently discuss new options for eczema with your healthcare team.

Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...

Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced that it has initiated two ...

In spite of its commonality, there are still plenty of unknowns around atopic dermatitis, including the actual cause of the skin condition. Perhaps that’s why there are so many myths surrounding it.

Children saw improvements in their atopic dermatitis with tapinarof regardless of their atopic comorbidities, according to ...

Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

Early trial results show stapokibart improves paediatric atopic dermatitis with good tolerability. Find out more about its potential as a new treatment option.